Norfloxacin HCl | CAS# 68077-27-0 (HCl) | chemotherapeutic antibacterial agent

MedKoo Cat#: 414474 | Name: Norfloxacin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Norfloxacin HCl is the salt form of Norfloxacin Free Base, a synthetic chemotherapeutic antibacterial agent occasionally used to treat common as well as complicated urinary tract infections. It is a first generation synthetic fluoroquinolone (quinolone) and is approved for the treatment of urinary tract infections, prostatitis, and sexually transmitted diseases, although it is no longer used for the latter due to bacterial resistance.

Chemical Structure

Norfloxacin HCl

CAS#68077-27-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 414474

Name: Norfloxacin HCl

CAS#: 68077-27-0 (HCl)

Chemical Formula: C16H19ClFN3O3

Exact Mass: 355.1099

Molecular Weight: 355.79

Elemental Analysis: C, 54.01; H, 5.38; Cl, 9.96; F, 5.34; N, 11.81; O, 13.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

70458-96-7 (free base); 68077-27-0 (HCl); 85181-48-2 (glutamate); 100587-52-8 (succinil)

Synonym

Norfloxacin hydrochloride; Norfloxacin HCl

IUPAC/Chemical Name

1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

InChi Key

JJWDELPVPRCLQN-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H18FN3O3.ClH/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20;/h7-9,18H,2-6H2,1H3,(H,22,23);1H

SMILES Code

CCN1C=C(C(c2c1cc(N3CCNCC3)c(F)c2)=O)C(O)=O.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 355.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hubicka U, Krzek J, Walczak M. Stability of ciprofloxacin and norfloxacin in the presence and absence of metal ions in acidic solution. Pharm Dev Technol. 2010 Sep-Oct;15(5):532-44. doi: 10.3109/10837450903338379. Review. PubMed PMID: 19842796. 2: Chou CJ, Membrez M, Blancher F. Gut decontamination with norfloxacin and ampicillin enhances insulin sensitivity in mice. Nestle Nutr Workshop Ser Pediatr Program. 2008;62:127-37; discussion 137-40. doi: 10.1159/000146256. Review. PubMed PMID: 18626197. 3: Padeĭskaia EN. [Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections]. Antibiot Khimioter. 2003;48(9):28-36. Review. Russian. PubMed PMID: 15002177. 4: Miano L, Goldoni S, Tubaro A, Paradiso Galatioto G, Gandolfi P. Review of norfloxacin in lower urinary tract infections. Eur Urol. 1990;17 Suppl 1:13-8. Review. PubMed PMID: 2191864. 5: Wolfson JS, Hooper DC. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med. 1988 Feb;108(2):238-51. Review. PubMed PMID: 3277508. 6: Nalin DR. Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects. Eur J Cancer Clin Oncol. 1988;24 Suppl 1:S55-61. Review. PubMed PMID: 3280327. 7: Edlund C, Nord CE. Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects. Scand J Infect Dis Suppl. 1988;56:14-21. Review. PubMed PMID: 3074461. 8: Stein GE. Review of the bioavailability and pharmacokinetics of oral norfloxacin. Am J Med. 1987 Jun 26;82(6B):18-21. Review. PubMed PMID: 3300308. 9: Goldstein EJ. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Am J Med. 1987 Jun 26;82(6B):3-17. Review. PubMed PMID: 3111257. 10: Norrby SR. Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin. Scand J Infect Dis Suppl. 1986;48:7-19. Review. PubMed PMID: 3535056. 11: Ruiz-Palacios GM. Norfloxacin in the treatment of bacterial enteric infections. Scand J Infect Dis Suppl. 1986;48:55-63. Review. PubMed PMID: 3535054. 12: Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Dec;30(6):482-513. Review. PubMed PMID: 3908074. 13: Wise R. Norfloxacin--a review of pharmacology and tissue penetration. J Antimicrob Chemother. 1984 May;13 Suppl B:59-64. Review. PubMed PMID: 6234277. 14: Lucena MI, Andrade RJ, Sanchez-Martinez H, Perez-Serrano JM, Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J Gastroenterol. 1998 Nov;93(11):2309-11. Review. PubMed PMID: 9820434. 15: Stojiljković MP, Jovanović D. [Norfloxacin--its current role in pharmacotherapy]. Vojnosanit Pregl. 1998 May-Jun;55(3):291-304. Review. Serbian. PubMed PMID: 9720445. 16: Hadimeri H, Almroth G, Cederbrant K, Eneström S, Hultman P, Lindell A. Allergic nephropathy associated with norfloxacin and ciprofloxacin therapy. Report of two cases and review of the literature. Scand J Urol Nephrol. 1997 Oct;31(5):481-5. Review. PubMed PMID: 9406312. 17: Schaeffer AJ. Review of norfloxacin in complicated and recurrent urinary tract infections. Eur Urol. 1990;17 Suppl 1:19-23. Review. PubMed PMID: 2191865. 18: Hooper DC, Wolfson JS. Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles. Curr Clin Top Infect Dis. 1989;10:194-240. Review. PubMed PMID: 2679694. 19: Karb VB. Two new fluoroquinolones: ciprofloxacin and norfloxacin. J Neurosci Nurs. 1988 Oct;20(5):327-28. Review. PubMed PMID: 2976793. 20: Ueda Y, Matsumoto F. [Current antimicrobial agent series III: Norfloxacin]. Jpn J Antibiot. 1988 Jul;41(7):782-96. Review. Japanese. PubMed PMID: 3050183.